Back to list

Peanut Oral immunotherapy with Dupilumab

University of North Carolina at Chapel Hill


The purpose of this study is to see if adding the drug Dupilumab to peanut oral immunothearpy (OIT) will increase the tolerance to peanut in peanut allergic subjects.




Drug or Biologic



6 - 17 years


Study Population

6 to 17 year old subjects who have a history of peanut allergy.


Edwin Kim
Clinical Assistant Professor
Medicine-UNCP A Allergy and Immunology

For questions, contact:

Deanna Hamilton
(919) 962-4405

Recruitment Period End

September 1, 2019


Primary Location
Clinical and Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 6 - 17 years

Participant qualification(s) -Allergy to peanut -6 to 17 years old -positive skin test to peanut -positive peanut IgE -allergic reaction to peanut during a controled food challenge

Not eligible if: -Use of Dupilumab in the past. -History of eosinophilic GI disease -Other uncontrolled chronic health conditions -Unable to stop antihistamines for study procedures

Number of Visits

    » 25 In person visit(s)

    1 screening, 4 food challenges, 2 SQ injection visits, 12, updosing visits, 4 maintenance visits, 4 follow up visits,

    » 5 Remote visit(s)

    5 phone visits

Participation Period

1 year 6 months


100 to 200 dollars per visit.

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.